期刊文献+
共找到13篇文章
< 1 >
每页显示 20 50 100
喃氟啶从Poloxamer407凝胶基质中的体外释放 被引量:2
1
作者 王文俭 刘祚永 +2 位作者 辛艳茹 袁默 蒋雪涛 《中国临床药学杂志》 CAS 1998年第5期233-235,共3页
目的:观察Poloxamer 407凝胶的形成及液体/凝胶互相转化的条件和喃氟啶在该凝胶中的体外释放.方法:以磷酸盐缓冲液[pH(7.40±0.01)作为Poloxamer 407的稀释剂,以喃氟啶作为实验药物做体外溶出.结果:Poloxmer 407的浓度在15%~40%之... 目的:观察Poloxamer 407凝胶的形成及液体/凝胶互相转化的条件和喃氟啶在该凝胶中的体外释放.方法:以磷酸盐缓冲液[pH(7.40±0.01)作为Poloxamer 407的稀释剂,以喃氟啶作为实验药物做体外溶出.结果:Poloxmer 407的浓度在15%~40%之内时,随着温度从0℃上升到37℃,其混合物从液体迅速转化成凝胶.相变温度随着Poloxamer407的浓度升高而降低.喃氟啶在该凝胶中的体外释放为零级释放,且随Poloxamer 407浓度的增加,释放速度变慢.8h时.含Poloxamer 407分别为20%,25%,30%,35%(m/m)的凝胶中时喃氟啶的累积释放率分别是(98.22±0.12)%,(86.20±0.20)%,(68.25±0.14)%,(50.02±0.08)%.结论:鉴于Poloxamr 407所具有的特殊的逆温相变性质,作为血管外注射型缓释植入剂的载体是有前途的. 展开更多
关键词 喃氟啶 poloxamer407 缓释制剂 凝胶基质
下载PDF
瑞舒伐他汀对poloxamer407诱导的小鼠高血脂模型血脂水平的影响 被引量:2
2
作者 李红涛 张婷婷 +6 位作者 马波 王晓东 李春进 包春艳 吴书元 杨涛 宋光明 《世界临床药物》 CAS 2012年第3期156-159,共4页
目的观察瑞舒伐他汀对poloxamer 407(P-407)诱导的小鼠高血脂模型血脂水平的影响。方法小鼠于腹腔注射P-407前先以瑞舒伐他汀(2或10 mg/kg)连续灌胃,并于腹腔注射P-407(0.3 g/kg)后3 h再次灌胃瑞舒伐他汀。以注射P-407前及注射后第3、4... 目的观察瑞舒伐他汀对poloxamer 407(P-407)诱导的小鼠高血脂模型血脂水平的影响。方法小鼠于腹腔注射P-407前先以瑞舒伐他汀(2或10 mg/kg)连续灌胃,并于腹腔注射P-407(0.3 g/kg)后3 h再次灌胃瑞舒伐他汀。以注射P-407前及注射后第3、4、24及48 h血甘油三酯和胆固醇水平评价瑞舒伐他汀的疗效,同时观察造模后24 h高密度脂蛋白-胆固醇水平。结果瑞舒伐他汀组血清甘油三酯和胆固醇水平减低,具有显著的量效关系,且作用可持续至造模后的48 h。瑞舒伐他汀组小鼠造模后24 h血清高密度脂蛋白-胆固醇水平显著升高(P<0.05)。结论瑞舒伐他汀可有效降低P-407诱导的高血脂模型小鼠的血脂水平。 展开更多
关键词 瑞舒伐他汀 poloxamer407 高血脂
原文传递
左氧氟沙星热敏型眼用凝胶的研制及体外释放研究 被引量:42
3
作者 高斐 王东凯 +3 位作者 罗立 徐松林 刘莱 徐飒 《中国药房》 CAS CSCD 北大核心 2005年第14期1057-1059,共3页
目的:制备左氧氟沙星热敏型眼用凝胶,并对其体外释放行为进行考察。方法:以泊洛沙姆407为热敏型材料制备左氧氟沙星眼用凝胶,根据胶凝温度筛选泊洛沙姆407的最佳处方浓度,采用无膜溶出模型对该制剂的体外释放行为进行考察。结果:左氧氟... 目的:制备左氧氟沙星热敏型眼用凝胶,并对其体外释放行为进行考察。方法:以泊洛沙姆407为热敏型材料制备左氧氟沙星眼用凝胶,根据胶凝温度筛选泊洛沙姆407的最佳处方浓度,采用无膜溶出模型对该制剂的体外释放行为进行考察。结果:左氧氟沙星检测浓度线性范围为3~11μg/ml(r=0.9991,n=6),回收率为99.62%;泊洛沙姆407在处方中的最佳浓度为18%;药物释放呈零级动力学特征,释放量取决于凝胶溶蚀量。结论:该制剂制备方法简单,用药剂量易于控制,极具开发前景。 展开更多
关键词 左氧氟沙星 泊洛沙姆407 热敏型眼用凝胶 体外释放 无膜溶出模型
下载PDF
三氧化二砷-泊洛沙姆407缓释剂瘤内注射治疗裸鼠人肝癌移植瘤的实验研究 被引量:4
4
作者 张鹏 王文 +3 位作者 行利 杜永平 冯佳 保宏祥 《临床肿瘤学杂志》 CAS 2009年第4期293-296,共4页
目的:观察三氧化二砷-泊洛沙姆407(As2O3-P407)缓释剂对裸鼠皮下人肝癌移植瘤的有效性。方法:以人肝癌HepG2细胞为来源建立裸鼠皮下移植瘤模型,实验共分3组:As2O3-P407缓释剂治疗组、As2O3治疗组和生理盐水(NS)对照组,于造模成功后6~8... 目的:观察三氧化二砷-泊洛沙姆407(As2O3-P407)缓释剂对裸鼠皮下人肝癌移植瘤的有效性。方法:以人肝癌HepG2细胞为来源建立裸鼠皮下移植瘤模型,实验共分3组:As2O3-P407缓释剂治疗组、As2O3治疗组和生理盐水(NS)对照组,于造模成功后6~8天行瘤体注射,每4天1次,共4次。比较各组抗癌疗效,观察裸鼠体重、肿瘤体积变化、抑瘤率、肿瘤组织病理及骨髓涂片以及裸鼠的存活情况、生存质量。结果:As2O3-P407缓释剂治疗组肿瘤生长受到显著抑制,肿瘤体积较As2O3组小(P<0.05),瘤重分别为(0.257±0.080)g和(0.641±0.109)g,差异有统计学意义(P<0.05);两组与NS对照组瘤重(1.094±0.147)g相比,差异有统计学意义(P<0.05)。治疗后As2O3-P407缓释剂组裸鼠体重大于As2O3组和NS对照组,差异有统计学意义(P<0.05)。各组均未见骨髓抑制现象。结论:As2O3-P407缓释剂瘤内注射,使用安全,可维持局部有效药物浓度、延长作用时间,疗效优于As2O3注射液。 展开更多
关键词 三氧化二砷 泊洛沙姆407 肝癌 介入治疗
下载PDF
三氧化二砷-泊洛沙姆407缓释剂治疗裸鼠肝癌移植瘤的作用与机制 被引量:2
5
作者 王文 张金洲 +5 位作者 张鹏 行利 杜永平 李锋 姚菊峰 王长海 《中西医结合肝病杂志》 CAS 2010年第6期350-352,I0006,共4页
目的:对比三氧化二砷(As2O3)-泊洛沙姆407缓释剂(As2O3-P407)与亚砷酸注射液(As2O3溶液)对裸鼠肝癌移植瘤的疗效并探讨可能机制。方法:以人肝癌HepG2细胞为来源建立裸鼠皮下移植瘤模型,实验共分3组,As2O3-P407缓释制剂治疗组(As2O3-P407... 目的:对比三氧化二砷(As2O3)-泊洛沙姆407缓释剂(As2O3-P407)与亚砷酸注射液(As2O3溶液)对裸鼠肝癌移植瘤的疗效并探讨可能机制。方法:以人肝癌HepG2细胞为来源建立裸鼠皮下移植瘤模型,实验共分3组,As2O3-P407缓释制剂治疗组(As2O3-P407组),As2O3治疗组(As2O3组)与生理盐水对照组(NS组),于造模后6~8天分别行瘤体注射每4天1次,4次为1个疗程。观察各组裸鼠治疗前后肿瘤体积变化及抑瘤率,各组裸鼠肿瘤组织分别行HE染色、TUNEL法检测、透射电镜观察,对比病理改变及肿瘤细胞的凋亡情况。结果:治疗后As2O3-P407组裸鼠肿瘤体积较As2O3组和NS组明显缩小(P<0.05);两治疗组抑瘤率分别为72%和46%;光镜下各治疗组肿瘤组织病理改变有意义;As2O3-P407组肿瘤细胞凋亡率明显高于As2O3组;电镜超微结构同样提示As2O3-P407组肿瘤凋亡细胞增加。结论:As2O3-P407缓释剂瘤内注射,可维持局部有效药物浓度、延长作用时间,疗效优于普通AsO注射液瘤内注射,其作用机制可能与增加肿瘤细胞凋亡有关。 展开更多
关键词 三氧化二砷 泊洛沙姆407 肝肿瘤 介入治疗 凋亡
下载PDF
两种去甲斑蝥素注射剂型对小鼠移植性肝癌抑制作用比较 被引量:3
6
作者 朱立峰 顾伟 +2 位作者 沈婕 张亚妮 李柏 《山东中医药大学学报》 2007年第1期64-67,共4页
目的:比较去甲斑蝥素注射液普通剂型和缓释剂型的抗肿瘤效果,研发增强去甲斑蝥素抗肿瘤作用的新剂型。方法:选择药物缓释辅料泊洛沙姆407,将去甲斑蝥素制成注射用缓释剂,观察其对小鼠H 22皮下移植瘤和腹水瘤的抗肿瘤效果。结果:缓释剂... 目的:比较去甲斑蝥素注射液普通剂型和缓释剂型的抗肿瘤效果,研发增强去甲斑蝥素抗肿瘤作用的新剂型。方法:选择药物缓释辅料泊洛沙姆407,将去甲斑蝥素制成注射用缓释剂,观察其对小鼠H 22皮下移植瘤和腹水瘤的抗肿瘤效果。结果:缓释剂型组对小鼠皮下肿瘤的抑瘤率为53.7%,优于普通剂型组的26.0%(P<0.05);缓释剂型组对小鼠腹水瘤的生命延长率为40.2%,优于普通剂型组的19.6%(P<0.01)。结论:去甲斑蝥素缓释剂型注射液的抗肿瘤效果优于普通剂型注射液。 展开更多
关键词 去甲斑蝥素 肝癌 泊洛沙姆407
下载PDF
卡介苗联合药物缓释剂在抗肿瘤方面的初步研究 被引量:1
7
作者 刘嘉琳 林萍萍 +5 位作者 周炳娟 刘书哲 吴艳萍 张颖 高伟敏 薛娟 《河北职工医学院学报》 2007年第3期3-5,共3页
目的初步探讨卡介苗(BCG)联合药物缓释剂的抗肿瘤性。方法建立大鼠肿瘤动物模型并给予不同BCG处理,取新鲜胸腺组织,行胸腺细胞增殖和凋亡的流式细胞学检测,并取皮下肿瘤常规制备石蜡切片行HE染色,光镜观察肿瘤内的形态变化。结果①造模... 目的初步探讨卡介苗(BCG)联合药物缓释剂的抗肿瘤性。方法建立大鼠肿瘤动物模型并给予不同BCG处理,取新鲜胸腺组织,行胸腺细胞增殖和凋亡的流式细胞学检测,并取皮下肿瘤常规制备石蜡切片行HE染色,光镜观察肿瘤内的形态变化。结果①造模后7天、14天,注射BCG及BCG结合泊洛沙姆407(P407)组肿瘤组织坏死明显,肿瘤周围有明显的纤维化。②BCG与P407混合液处理组胸腺细胞凋亡率明显低于空白对照组,而增殖指数明显高于该组;BCG原液在造模后7天时,胸腺细胞凋亡率与空白对照组相比无显著差异,而增殖指数明显高于该组,造模后14天时,胸腺细胞凋亡率及增殖指数均明显高于正常对照组。结论P407可增强BCG的抗肿瘤作用。 展开更多
关键词 大鼠 动物模型 卡介苗 泊洛沙姆407(P407) 明胶
下载PDF
苄达赖氨酸眼用温敏凝胶的制备 被引量:6
8
作者 冼远芳 李微 +2 位作者 郝游游 杨国清 高喜安 《华西药学杂志》 CAS CSCD 北大核心 2011年第3期268-270,共3页
目的制备苄达赖氨酸眼用温敏凝胶并考察其性能。方法采用冷溶法制备温敏凝胶;试管倒转法考察凝胶浓度、药物含量对相转变温度的影响;无膜溶出法模拟眼部生理环境,考察凝胶的体外溶蚀和药物释放行为。结果转变温度随凝胶溶液浓度而发生变... 目的制备苄达赖氨酸眼用温敏凝胶并考察其性能。方法采用冷溶法制备温敏凝胶;试管倒转法考察凝胶浓度、药物含量对相转变温度的影响;无膜溶出法模拟眼部生理环境,考察凝胶的体外溶蚀和药物释放行为。结果转变温度随凝胶溶液浓度而发生变化;含药量对相变温度无影响;优化处方为泊洛沙姆407浓度17.33%、药物的含量为1 mg·mL-1、溶剂为pH7.4的磷酸缓冲溶液、温敏凝胶转变温度为25.82℃。结论制备的苄达赖氨酸眼用温敏凝胶满足眼部用药的要求,可延长药物在眼部的作用时间。 展开更多
关键词 眼用温敏凝胶 苄达赖氨酸 泊洛沙姆407 相转变温度 体外释放
原文传递
盐酸倍他洛尔离子/温度敏感型眼用原位凝胶的制备与评价 被引量:3
9
作者 袁洁 王慧娟 +1 位作者 郭东贵 周英 《中国医院药学杂志》 CAS CSCD 北大核心 2013年第14期1137-1141,共5页
目的:制备盐酸倍他洛尔离子/温度敏感型眼用原位凝胶,建立药物的含量测定方法并进行体外评价。方法:以脱乙酰结冷胶和泊洛沙姆407作为基质制备凝胶;采用高效液相色谱法测定药物含量;采用无膜溶出模型和离体角膜渗透实验研究药物的体外... 目的:制备盐酸倍他洛尔离子/温度敏感型眼用原位凝胶,建立药物的含量测定方法并进行体外评价。方法:以脱乙酰结冷胶和泊洛沙姆407作为基质制备凝胶;采用高效液相色谱法测定药物含量;采用无膜溶出模型和离体角膜渗透实验研究药物的体外释放行为。结果:原位凝胶处方组成为主药0.28%,载体为0.5%的脱乙酰结冷胶和9%的泊洛沙姆407,等渗调节剂为5%的甘露醇,抑菌剂为0.03%的羟苯乙酯。与盐酸倍他洛尔溶液剂相比,该制剂的药物透过速度慢。结论:该制剂制备工艺简便,具有缓释特性。 展开更多
关键词 盐酸倍他洛尔 离子 温度敏感型原位凝胶 脱乙酰结冷胶 泊洛沙姆407 制备 体外释药研究
原文传递
Amino-functionalized poloxamer 407 with both mucoadhesive and thermosensitive properties:preparation, characterization and application in a vaginal drug delivery system 被引量:12
10
作者 Liqian Ci Zhigang Huang +3 位作者 Yu Liub Zhepeng Liu Gang Wei Weiyue Lu 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2017年第5期593-602,共10页
Lack of mucoadhesive properties is the major drawback to poloxamer 407(F127)-based in situ hydrogels for mucosal administration. The objective of the present study was to construct a novel mucoadhesive and thermosensi... Lack of mucoadhesive properties is the major drawback to poloxamer 407(F127)-based in situ hydrogels for mucosal administration. The objective of the present study was to construct a novel mucoadhesive and thermosensitive in situ hydrogel drug delivery system based on an aminofunctionalized poloxamer for vaginal administration. First, amino-functionalized poloxamer 407(F127-NH2) was synthesized and characterized with respect to its micellization behavior and interaction with mucin. Then using acetate gossypol(AG) as model drug, AG-loaded F127-NH2-based in situ hydrogels(NFGs) were evaluated with respect to rheology, drug release, ex vivo vaginal mucosal adhesion, in vivo intravaginal retention and local irritation after vaginal administration to healthy female mice. The results show that F127-NH2 is capable of forming a thermosensitive in situ hydrogel with sustained drug release properties. An interaction between positively charged F127-NH2 and negatively charged mucin wasrevealed by changes in the particle size and zeta potential of mucin particles as well as an increase in the complex modulus of NFG caused by mucin. Ex vivo and in vivo fluorescence imaging and quantitative analysis of the amount of AG remaining in mouse vaginal lavage all demonstrated greater intravaginal retention of NFG than that of an unmodified F127-based in situ hydrogel. In conclusion, amino group functionalization confers valuable mucoadhesive properties on poloxamer 407. 展开更多
关键词 Poloxamer 407 Amino group Acetate gossypol In situ hydrogel Mucoadhesive gel
原文传递
A novel rat model of fatty organ degeneration induced by poloxamer 407 被引量:1
11
作者 Na Yin Ting Chu +6 位作者 Yingfu Peng Yuanchun Yao Jingjing Li Bo Xiang Bo Yang Thomas P.Johnston Maosheng Yang 《Journal of Bio-X Research》 2019年第1期41-45,共5页
Traditional methods of inducing hyperlipidemia in animal models are either costly(genetic manipulation)or it is difficult to control for the effects of other variables.For example,during high-fat feeding,the amount of... Traditional methods of inducing hyperlipidemia in animal models are either costly(genetic manipulation)or it is difficult to control for the effects of other variables.For example,during high-fat feeding,the amount of high-fat diet intake per animal cannot be precisely controlled.The aim of this study was to develop an experimental model of fatty organ degeneration induced by poloxamer 407(P-407).The study was conducted in 2-month-old,male Sprague-Dawley rats that were administered intraperitoneally with either 10%(w/w)P-407(1 g/kg)or saline(10 mL/kg)for 4 months.Their lipid profile,organ degeneration due to fat deposition,and body mass were assessed.Intraperitoneal administration of P-407 resulted in significant increases in plasma triglycerides(P0.001),total cholesterol(P<0.001),high-density lipoprotein-cholesterol(P0.001),and low-density lipoprotein(P<0.001)cholesterol.In contrast to the control group,fatty tissue degeneration was observed in the liver,spleen,and kidneys of P-407-treated rats.Positive correlations between fatty tissue degeneration,and the atherogenic index of plasma(P<0.001)and the ratio of total cholesterol to high-density-lipoprotein(P<0.001)were identified.In addition,treatment with P-407 for 3 to 4 months caused a significant reduction in body mass relative to controls(P<0.001).Thus,this study describes the development of a cost-effective experimental rat model of organ degeneration,characterized by fat accumulation in the liver,spleen,and kidneys,which could be used for the study of steatosis and related diseases arising from sustained untreated dyslipidemia.Furthermore,both the atherogenic index of plasma and the ratio of total cholesterol to high-density lipoprotein-cholesterol can be used to predict the risk of fatty tissue degeneration in this model.The study was approval of the University of Jishou Biomedical Research Ethics Committee,China. 展开更多
关键词 atherogenic index of plasma fatty degeneration HYPERLIPIDEMIA intraperitoneal administration poloxamer 407 rat model TRIGLYCERIDE
原文传递
Enhanced bioavailability and biosafety of cannabidiol nanomicelles for effective anti-inflammatory therapy
12
作者 Yuan Rao Runwei Li +5 位作者 Saixing Liu Linchao Meng Qilin Wu Qipeng Yuan Hao Liang Meng Qin 《Particuology》 SCIE EI CAS CSCD 2022年第10期1-9,共9页
Cannabidiol(CBD)shows great anti-inflammatory potential;however,the hydrophobicity and strong first-pass effect of CBD leads to its extremely low oral bioavailability.Poloxamer 407(P407)is a tri-block copolymer compos... Cannabidiol(CBD)shows great anti-inflammatory potential;however,the hydrophobicity and strong first-pass effect of CBD leads to its extremely low oral bioavailability.Poloxamer 407(P407)is a tri-block copolymer composed of(poly)ethylene oxide(PEO)and(poly)propylene oxide(PPO)sections.It has a PEO-PPO-PEO structure,which is widely used in the preparation of drug delivery systems that are highly biocompatible.When it reaches a certain concentration in water,P407 can self-assemble into a micelle structure containing a hydrophobic core and a hydrophilic shell.A potential approach to enhanc-ing the oral bioavailability of hydrophobic drugs incorporating them into the hydrophilic carrier.We prepared CBD nanomicelles with a drug loading of 14.29%by a cosolvent evaporation method using P407 with appropriate antioxidants.Cell experiments indicated that anti-inflammatory markers(IL-4 and IL-10)increased,while inflammatory markers(TNF-αand IL-6)decreased.Moreover,animal experiments showed that inflammatory cells were inhibited by CBD nanomicelles,and the anti-inflammatory effect of micelles was better than that of CBD,while no obvious evidence indicated toxicity to the liver and kidney. 展开更多
关键词 CBD Poloxamer 407 Polymeric micelle ANTI-INFLAMMATORY CYTOTOXICITY
原文传递
Genistein-loaded poloxamer 403/407 mixed micelles: preparation and pharmacokinetic study in rats
13
作者 Yan Cai Wei Dai +2 位作者 Fuhua Qin Jieyin Sun Ruilong Wei 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2018年第5期342-351,共10页
In the present study, we aimed to prepare poloxamer 403/407 mixed micelles in order to improve the solubility and oral bioavailability of genistein. Genistein was incorporated in the mixed poloxamer micelles by thin-f... In the present study, we aimed to prepare poloxamer 403/407 mixed micelles in order to improve the solubility and oral bioavailability of genistein. Genistein was incorporated in the mixed poloxamer micelles by thin-film hydration method, and its physicochemical properties, including particle size, zeta potential, entrapment efficiency and drug loading, were investigated. In vitro release of genistein from the mixed micelles was monitored by dialysis method, and pharmacokinetic study of genistein loaded mixed micelles was carried out in rats. We found that the particle size and zeta potential of mixed micelles were(20.31±0.43) nm and(–8.94±0.35) m V, with encapsulation efficiency 90.59%±0.67% and drug loading 7.74%±0.05%. Solubility of genistein in mixed micelles reached 3.80 mg/m L, which was about 130 times higher than that in water. Genistein-loaded mixed micelles showed sustained release characteristics in vitro with no burst release phenomenon, but it was faster than suspension. The AUC0–t and AUC0–∞ of mixed micelles were 196.74% and 204.62% greater than that of genisein suspension, respectively. Consequently, poloxamer 403/407 mixed micelles significantly improved the solubility and oral bioavailability of genistein, which could be used as an effective drug delivery system for oral administration of poorly soluble drugs. 展开更多
关键词 GENISTEIN Poloxamer 407 Poloxamer 403 Micelles PHARMACOKINETICS
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部